# PharmaCyte Biotech, Inc. (PMCB)

> Source: Nexqual · https://nexqual.com/PMCB · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, PharmaCyte Biotech, Inc. (PMCB), nexqual.com/PMCB" · informational, not investment advice.

**Price:** USD 0.36 (+2.11% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.36 · day 0.34–0.36 · 52w 0.33–1.51 · market cap null · NCM

## Key facts
- Last four reported quarters (through Jul 31, 2026): revenue $0K, net income -$16.1M (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -63.3% vs S&P 500 +18.1%; 5Y -88.2% vs S&P 500 +85.1%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0K | $0K | $0K | $0K | $0K | $0K |
| Operating income | -$4.4M | -$6.5M | -$8.5M | -$4.4M | -$6.9M | -$7.0M |
| Net income | -$4.2M | -$4.3M | $334K | $30.7M | -$19.4M | -$16.1M |
| EPS (diluted) | -$0.27 | -$0.22 | -$1.80 | $3.19 | -$2.77 | — |
| Cash + short-term investments | $85.4M | $68.0M | $50.2M | $15.5M | $18.9M | — |
Fiscal years end Apr. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jul 31, 2026)

P/E at fiscal year-ends: Apr 2025 0.3x, Apr 2024 60.9x.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -63.3% | -88.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -63.5% | -34.8% |
| Volatility (annualized) | 91.4% | 49.9% |
| Max drawdown | -71.4% (Dec 2025→Oct 2026) | -88.7% (May 2023→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/PMCB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt